A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
2,749actual
Sites
358
Countries
Argentina, Austria, Brazil +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-04-03 | actual | When the study began enrolling |
| Primary completion | 2026-03-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-16 | actual | The whole study's end, after follow-up |
| First posted | 2023-04-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Type 2 Diabetes
- Obesity
- Overweight or Obesity
- Overweight
- Cardiovascular Diseases
- Chronic Kidney Disease
Interventions
- Drug: Orforglipron — also filed as LY3502970
- Drug: Insulin Glargine
Primary outcome
what the primary-completion date above is the date OFTime to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI), Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death]
measured Baseline to End of the Study (Approximate Maximum 104 Weeks)
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed